Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
GD2-CAR-NK in combination with Smac Mimetics: A Novel Therapeutic Strategy Against High-Risk Neuroblastoma
EF 2021-22
Résumé
Neuroblastoma (NB) is the second most common pediatric solid tumor cancer of immature nerve cells. NB tumors have a diverse range of clinical behaviors, from spontaneous regression in infants under 24 months to a highly recurrent and aggressive malignancy in children older than 24 months.The current therapies for high-risk NB are multi-modal, involving surgery, radiation, and high-dose combination chemotherapy. These therapies carry significant harmful side effects, such as neurological and developmental problems. Furthermore, high-risk NB patients tend to resist these treatments and have a higher chance of tumor recurrence. Therefore, it is imperative to invest in developing new targeted therapeutics against high-risk NB that improve clinical outcomes and patient quality of life. I aim to combine two different current treatment techniques that capitalize on the cytotoxic activity of NK cells along with the specific antibody-mediated recognition of NB cells. I will also use a family of experimental cancer drugs called SMAC mimetics to increase NK cytotoxicity and persistence, which are common issues faced with these types of treatments. I plan to ensure the safety and efficacy of the therapeutic in animal and neuroblastoma models, providing an improved targeted tool to fight high-risk NB tumors.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
467077
Name
Hakoum Mariam
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
GD2-CAR-NK in combination with Smac Mimetics: A Novel Therapeutic Strategy Against High-Risk Neuroblastoma
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Cancer Therapy; Car-Nk; Combination Therapy; Immune Response; Immune Stimulation; Immunotherapy; Neuroblastoma; Pediatric Cancer; Smac Mimetics
Abstract
Neuroblastoma (NB) is the second most common pediatric solid tumor cancer of immature nerve cells. NB tumors have a diverse range of clinical behaviors, from spontaneous regression in infants under 24 months to a highly recurrent and aggressive malignancy in children older than 24 months.The current therapies for high-risk NB are multi-modal, involving surgery, radiation, and high-dose combination chemotherapy. These therapies carry significant harmful side effects, such as neurological and developmental problems. Furthermore, high-risk NB patients tend to resist these treatments and have a higher chance of tumor recurrence. Therefore, it is imperative to invest in developing new targeted therapeutics against high-risk NB that improve clinical outcomes and patient quality of life. I aim to combine two different current treatment techniques that capitalize on the cytotoxic activity of NK cells along with the specific antibody-mediated recognition of NB cells. I will also use a family of experimental cancer drugs called SMAC mimetics to increase NK cytotoxicity and persistence, which are common issues faced with these types of treatments. I plan to ensure the safety and efficacy of the therapeutic in animal and neuroblastoma models, providing an improved targeted tool to fight high-risk NB tumors.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hakoum, Mariam
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~